DX-9065a inhibition of factor Xa and the prothrombinase complex: Mechanism of inhibition and comparison with therapeutic heparins

Thrombosis and Haemostasis

Volumn 89, Issue 1, 2003, Pages 112-121

  Rezaie, Alireza R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin; DX 9065a; Factor Xa; Heparin; Prothrombinase

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; PROTHROMBIN; THROMBIN; TYROSINE;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; CATALYST; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTHROMBIN TIME;

EID: 0037250429     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613550     Document Type: Article

References (44)

1. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 1988; 57: 915-56.
2. Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-83.
3. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ, Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
4. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-7.
5. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991; 353: 576-8.
6. Olson ST, Björk I. Regulation of thrombin by antithrombin and heparin cofactor II. In: Berliner LJ ed. Thrombin: Structure and Function, New York, NY: Plenum Press 1992.
7. Huang Z-F, Wun T-C, Broze GJ, Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-5.
8. Jin L, Abrahams J, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci (USA) 1997; 94: 14683-8.
9. Rezaie AR. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla-domain antagonism of heparin binding to factor Xa. J Biol Chem 1998; 273: 16824-7.
10. Rezaie AR, Olson ST. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa binding complex. Demonstration by rapid kinetics studies. Biochemistry 2000; 39: 12083-90.
11. Miletich JP, Jackson CM, Majerus PW. Properties of the Factor Xa binding site on human platelets. J Biol Chem 1978; 253: 6908-16.
12. Walker FJ, Esmon CT. The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III. Biochem Biophys Res Commun 1979; 90:641-7.
13. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-91.
14. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97: 2309-13.
15. Schoen P, Lindhout T. Flow and the inhibition of prothrombinase by antithrombin III and heparin. Blood 1991; 78: 118-24.
16. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62.
17. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CN, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitor antistatin and tick anticoagulant peptide (TAP) in rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-62.
18. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993; 70: 212-6.
19. Jordan SP, Mao S-S, Lewis SD, Shafer JA. Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. Biochemistry 1992; 31: 5374-80.
20. Krishnaswamy S, Vlasuk GP, Bergum PW. Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 1994; 33: 7897-907.
21. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9.
22. Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DK-9065a, a highly selective factor Xa inhibitor. Thromb Res 1995; 80: 99-104.
23. Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485-91.
24. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-9.
25. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 Å crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg chlorometheylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-75.
26. Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des (1-45) factor Xa at 2.2 Å resolution. J Mol Biol 1993; 232: 947-66.
27. Rezaie AR, Yang L. Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin. Biochem Biophys Acta 2001; 1528: 167-76.
28. Rezaie AR. Role of residue 99 at the S2 subsite of factor Xa and activated protein C in enzyme specificity. J Biol Chem 1996; 271: 23807-14.
29. Smirnov MD, Esmon CT. Phosphatidyl-ethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
30. Rezaie AR, He X, Esmon CT. Thrombomodulin increases the rate of thrombin inhibition by BPTI. Biochemistry 1998; 37: 693-9.
31. Rezaie AR, Esmon CT. Molecular basis of residue 192 participation in determination of coagulation protease specificity. Eur J Biochem 1996; 242: 477-84.
32. Copeland RA. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis. New York: Wiley-VCH 2000.
33. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-60.
34. Krishnaswamy S, Betz A. Exosites determines macromolecular substrate recognition by prothrombinase. Biochemistry 1997; 36: 12080-6.
35. Schoen P, Lindhout T, Willems G, Hemker HC. Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. J Biol Chem 1989; 264: 10002-7.
36. Ellis V, Scully MF, Kakkar VV. The acceleration of the inhibition of platelet prothrombinase complex by heparin. Biochem J 1986; 233: 161-5.
37. Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U. The effect of calcium, phospholipid factor V on hte anti-(factor Xa) activity of heparin and its high-affinity oligosaccharide. Biochem J 1987; 243: 31-7.
38. Brufatto N, Nesheim ME. The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. J Biol Chem 2001; 276: 17663-71.
39. Katakura S-I, Nagahara T, Hara T, Iwamoto M. A novel factor Xa inhibitor: Structure-activity relationships and selectivity between factor Xa and thrombin. Biochem Biophys Res Commun 1993; 197: 965-72.
40. Lin Z, Johnson ME. Proposed cation-p mediated binding by factor Xa: A novel enzymatic mechanism for molecular recognition. FEBS Letters 1995; 370: 1-5.
41. Brandstetter H, Kuhne A, Bode W, Huber R, Von Der Saal W, Wirthensohn K, Engh RA. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem 1996; 271: 29988-92.
42. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
43. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17: 259-91.
44. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-5.